Nyam Kamsu-Kom

<i>RAS</i> Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Patrick A. Oberholzer, Damien Kee, Piotr Dziunycz et al. · Journal of Clinical Oncology · 2011 · 381 citations · Full text

Medicine, Oncology, Pharmacology +16

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

Lise Boussemart, Hélène Malka-Mahieu, Isabelle Girault et al. · Nature · 2014 · 360 citations

Medicine, Cancer Biology, Oncology +11

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

Lise Boussemart, Émilie Routier, Céu Mateus et al. · Annals of Oncology · 2013 · 205 citations · Full text

Medicine, Dermatology, Pharmacology +11

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Clélia Coutzac, Julien Adam, Émilie Soularue et al. · Journal of Crohn s and Colitis · 2017 · 166 citations

Life Sciences, Immunology, Pathology +17

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i>

J.-P. Arnault, Christine Mateus, Bernard Escudier et al. · Clinical Cancer Research · 2011 · 120 citations · Full text

Medicine, Dermatology, Oncology +17